Company news
Instil Bio, Inc. news in 2021
Instil Bio, Inc.'s news releases, calls and decks from 2021, newest first.
Instil Bio Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 14, 2021
Instil Bio Announces Poster Presentations at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 14, 2021
Instil Bio Presents Subset Analysis of Patients with Checkpoint-Refractory Advanced Melanoma from Compassionate Use Study at 2021 ESMO Congress
September 15, 2021
Instil Bio Receives IND Clearance to Initiate a Phase 2 Clinical Trial for Patients with Advanced Melanoma
September 12, 2021
Instil Bio Reports Second Quarter 2021 Financial Results and Provides Corporate Update
August 11, 2021
Instil Bio Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 12, 2021
Instil Bio Receives Orphan Drug Designation for ITIL-168 in Melanoma
April 26, 2021
Instil Bio Presents Clinical Data in Metastatic Melanoma in a Late-Breaking e-Poster at the 2021 American Association for Cancer Research (AACR) Annual Meeting
April 11, 2021
Instil Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
March 22, 2021
Instil Bio Announces Pricing of Upsized Initial Public Offering
March 17, 2021